Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8896 results

  1. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  2. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  3. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Withdrawn guidance

  4. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  5. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Withdrawn guidance

  6. Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

    We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

    Withdrawn guidance

  7. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

    Withdrawn guidance

  8. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Withdrawn guidance

  9. Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)

    This guidance has been updated and replaced by NICE technology appraisal guidance 604.

    Withdrawn guidance

  10. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    This guidance has been updated and replaced by NICE technology appraisal guidance 752.

    Withdrawn guidance

  11. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Withdrawn guidance

  12. Ischaemic heart disease - coronary artery stents (TA4)

    This guidance has been replaced by NICE technology appraisal guidance 71. 

    Withdrawn guidance

  13. The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)

    This guidance has been updated and replaced by NICE technology appraisal guidance 187.

    Withdrawn guidance

  14. Guidance on the use of metal on metal hip resurfacing arthroplasty (TA44)

    This guidance has been updated and replaced by NICE technology appraisal guidance 304.

    Withdrawn guidance

  15. Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

    This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

    Withdrawn guidance